Compare NRP & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRP | CAPR |
|---|---|---|
| Founded | 2002 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | N/A | N/A |
| Metric | NRP | CAPR |
|---|---|---|
| Price | $118.86 | $24.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $41.38 |
| AVG Volume (30 Days) | 51.9K | ★ 1.3M |
| Earning Date | 02-27-2026 | 03-18-2026 |
| Dividend Yield | ★ 2.62% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 10.92 | N/A |
| Revenue | ★ $218,701,000.00 | $11,130,509.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16,329.74 |
| P/E Ratio | $10.48 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $86.83 | $4.30 |
| 52 Week High | $123.40 | $40.37 |
| Indicator | NRP | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 68.99 | 54.85 |
| Support Level | $112.81 | $21.75 |
| Resistance Level | $116.85 | $23.86 |
| Average True Range (ATR) | 3.80 | 1.29 |
| MACD | -0.24 | -0.28 |
| Stochastic Oscillator | 53.97 | 80.39 |
Natural Resources Partners LP is a diversified natural resource company. It is engaged in the business of owning, managing and leasing a diversified portfolio of mineral properties in the United States, including interests in coal, trona and soda ash, crude oil and natural gas, construction aggregates, frac sand, and other natural resources. The company leases coal reserves to experience mine operators under long-term leases that grant the operator the right to mine its coal reserves in exchange for royalty payments. The company operates in two reportable segments namely: Mineral Rights and Soda Ash. the majority of the revenue is generated from the Mineral Rights segment. Geographically, the business activity of the group functions through the United States.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.